pubmed.ncbi.nlm.nih.gov

Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches - PubMed

  • ️Fri Jan 01 2021

Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches

Paul Dowling et al. Proteomes. 2021.

Abstract

Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells which are incapable of differentiating into mature leukocytes. AML risk stratification is based on genetic background, which also serves as a means to identify the optimal treatment of individual patients. However, constant refinements are needed, and the inclusion of significant measurements, based on the various omics approaches that are currently available to researchers/clinicians, have the potential to increase overall accuracy with respect to patient management. Using both nontargeted (label-free mass spectrometry) and targeted (multiplex immunoassays) proteomics, a range of proteins were found to be significantly changed in AML patients with different genetic backgrounds. The inclusion of validated proteomic biomarker panels could be an important factor in the prognostic classification of AML patients. The ability to measure both cellular and secreted analytes, at diagnosis and during the course of treatment, has advantages in identifying transforming biological mechanisms in patients, assisting important clinical management decisions.

Keywords: acute myeloid leukemia; biomarkers; immunoassay; mass spectrometry; proteomics.

PubMed Disclaimer

Conflict of interest statement

C.A.H. has received research funding from Celgene/BMS, Kronos Bio, Novartis, Oncopeptides, Orion Pharma and the IMI2 projects HARMONY and HARMONY PLUS unrelated to this work.

Figures

Figure 1
Figure 1

Pathway analysis (cells) comparing significant proteins found to be elevated in Group 1 (Gr1—favourable) and Group 3 (Gr3—adverse) when compared.

Figure 2
Figure 2

Pathway analysis (cells) comparing significant proteins found to be elevated in Group 1 (Gr1—favorable) and Group 2 (Gr2—intermediate) when compared.

Figure 3
Figure 3

Pathway analysis (cells) comparing significant proteins found to be elevated in Group 2 (Gr2—intermediate) and Group 3 (Gr3—adverse) when compared.

Figure 4
Figure 4

Box and Whisker plots for IL-17A, IL-1RA, SDF-1α1β and IL-1α based on results from serum biomarker analysis using targeted multiplexed immunoassays.

Similar articles

Cited by

References

    1. De Kouchkovsky I., Abdul-Hay M. Acute myeloid leukemia: A comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441. doi: 10.1038/bcj.2016.50. - DOI - PMC - PubMed
    1. Hao T., Li-Talley M., Buck A., Chen W. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States. Sci. Rep. 2019;9:12070. doi: 10.1038/s41598-019-48445-1. - DOI - PMC - PubMed
    1. Shallis R.M., Wang R., Davidoff A., Ma X., Zeidan A.M. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70–87. doi: 10.1016/j.blre.2019.04.005. - DOI - PubMed
    1. Zhang J., Gu Y., Chen B. Mechanisms of drug resistance in acute myeloid leukemia. OncoTargets Ther. 2019;12:1937–1945. doi: 10.2147/OTT.S191621. - DOI - PMC - PubMed
    1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 1985;103:620–625. doi: 10.7326/0003-4819-103-4-620. - DOI - PubMed